NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New HELIOS-B Data and Upbeat Financial Results
Alnylam Pharmaceuticals (ALNY) shared new results from its Phase 3 HELIOS-B study of vutrisiran, with data presented at the American Heart Association meeting. The findings demonstrate consistent efficacy and safety across key patient groups. The company also reported a strong third quarter, moving from net loss to net income and raising full-year revenue guidance. This combination has caught the attention of many investors.
See our latest analysis for Alnylam Pharmaceuticals.
Alnylam’s...